© 2025 HSP News Service, L.L.C.
Researchers may have uncovered genetic differences that may help predict response to immune checkpoint inhibitors among patients with metastatic melanoma, according to a recent study published by Monson et al in Nature Medicine. Background The investigation revolved around mitochondrial haplogroups ...
In the phase III ALASCCA trial, the use of adjuvant daily aspirin for 3 years reduced the risk of recurrence in colorectal cancer harboring PI3K pathway alterations by 51%, according to research in a Scandinavian population presented at the 2025 ASCO Gastrointestinal Cancers Symposium by Anna...
In a long-term follow-up of an Israeli phase II trial reported in a research letter in JAMA Oncology, Evron et al compared prophylactic radiation therapy (RT) of the contralateral breast vs surveillance in BRCA pathogenic variant carriers with early-stage breast cancer. Study Details In the...
Violaine Randrian, MD, PhD, of Memorial Sloan Kettering Cancer Center and CHU/Université de Poitiers, reviews gene-specific outcomes in patients with Lynch syndrome treated with immune checkpoint inhibitors for advanced cancer (Abstract 10504).
Researchers have identified a gene that could play a key role in the transition to a more aggressive, treatment-resistant type of prostate cancer, according to a recent study published by Duan et al in the Journal of Clinical Investigation. The findings indicated that the gene may be indirectly...
Researchers may have uncovered factors contributing to poor outcomes among patients with prostate cancer, according to recent findings presented by Dall’Era et al at the 2025 ASCO Annual Meeting (Abstract 5104). The findings may lead to the development of novel targeted therapies, particularly in...
Angela R. Bradbury, MD, of the University of Pennsylvania, presents findings from the eREACH trial—a randomized study of an eHEALTH delivery alternative for cancer genetic testing for hereditary predisposition in patients with metastatic cancers (Abstract 10502).
South Florida has a unique demographic, characterized by a large Hispanic population with ancestries from the Caribbean and Central and South America. Arelis Esther Martir-Negron, MD, of Miami Cancer Institute, presents data from a retrospective analysis that sought to determine the frequency and spectrum of BRCA pathogenic/likely pathogenic variants in this population (Abstract 10579).
Researchers may have uncovered early indications of the clinical benefit of niraparib in patients with advanced melanoma whose tumors have specific genetic changes impacting DNA repair, according to a recent study published by Kim et al in JCO Precision Oncology. Background The U.S. Food and Drug...
Investigators have uncovered how a specific sequence of cancer therapies could improve outcomes among patients with relapsed/refractory mature T- and natural killer (NK)-cell lymphomas, according to a recent study published by Sorial et al in the British Journal of Haematology. Background...
Researchers may have uncovered the role of Plasmodium falciparum malaria in the development of Burkitt lymphoma, according to a recent study published by Ariera et al in The Journal of Immunology. Background Uncomplicated malaria occurs when a patient’s symptoms are nonspecific, including fever,...
Using next-generation DNA sequencing, researchers have identified four specific genes whose mutations are linked to the development and progression of lethal stomach cancers. This could potentially enable practitioners to offer targeted treatments that would spare many patients from unnecessarily...
According to the results of a molecularly matched, tumor-agnostic phase II trial, the combination of the PARP inhibitor olaparib and the PD-1 inhibitor pembrolizumab demonstrated antitumor activity with no new safety signals, particularly in patients with BRCA1/2 mutations. Data from this...
Although next-generation sequencing to assist decision-making for genomics-driven therapy in patients with advanced solid tumors has traditionally been conducted using tissue biopsy samples, recent data support the use of plasma-based circulating tumor DNA (ctDNA) for the genomic profiling of solid ...
The oral KRAS G12D inhibitor zoldonrasib could provide clinical benefit in patients with previously treated non–small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation, according to new findings presented by Arbour et al at the 2025 American Association for Cancer Research (AACR)...
More than 20% of cancer-related claims for next-generation sequencing (NGS) from Medicare beneficiaries were denied between 2016 and 2021. Findings from a cohort study published in JAMA Network Open suggested that there is continued uncertainty about the boundaries of coverage for NGS, even with...
A new study showed that approximately 80% of patients with stage III melanoma who had detectable levels of circulating tumor DNA (ctDNA) before they started treatment to suppress their tumors went on to experience recurrence. Researchers also found that the disease returned more than four times...
A whole-genome sequencing–based, error-corrected method for detecting cancer from blood samples could be more sensitive and accurate in monitoring disease status posttreatment among patients with cancer compared with prior methods, according to a recent study published by Cheng et al in Nature...
Pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer, is also among the most deadly, with an average 5-year survival rate of less than 10%. The malignancy is often preceded by precancerous lesions. Traditional treatments of the cancer, including chemotherapy, surgery, and...
A newfound role for the cancer gene BRCA2 suggests why only select patients have benefited from treatment with PARP1 inhibitors to date. The results of a study by investigators at NYU Langone Health were recently published in the journal Nature. In brief, PARP inhibitors act by impairing...
The clinical application of BCR::ABL1 digital polymerase chain reaction (PCR) testing may reliably quantify stable deep molecular remission in patients with chronic myeloid leukemia (CML), which could help determine when maintenance therapy may be discontinued successfully, according to a recent...
In an Israeli retrospective cohort study reported as a research letter in JAMA Network Open, Armon et al found that presymptomatic awareness of BRCA1/BRCA2 pathogenic variant carrier status was associated with better outcomes in several measures in women with ovarian cancer. Study Details The...
Investigators have found that nearly 50% of women diagnosed with ovarian cancer may not be receiving the genetic testing that could help guide their treatment and potentially improve outcomes, according to a recent report conducted by the Ovarian Cancer Research Alliance (OCRA) and Komodo Health....
Investigators studied race-associated molecular differences in the pancreatic tumors of Black and White patients to determine whether such differences were associated with response to immunotherapy. The findings were published recently by Mandal et al in Cancer Research Communications and reinforce ...
Investigators may have uncovered nearly identical mutations to previously examined patient populations and several notable differences that may be clinically relevant among Black patients with ovarian cancer, according to a recent study published by Lawson-Michod et al in Cancer Research....
Researchers have uncovered a novel combination therapy leveraging the U.S. Food and Drug Administration (FDA)-approved KRAS inhibitor sotorasib and an experimental drug called FGTI-2734, which could improve the efficacy of precision medicine in patients with KRAS-mutated non–small cell lung cancer...
Investigators may have identified new strategies for use in the primary care setting to improve the detection of cancer-susceptibility genes, according to a recent study published by Swisher et al in JAMA Network Open. Background Up to 10% of cancers—including breast cancer, ovarian cancer,...
In a Children’s Oncology Group (COG) study reported in the Journal of Clinical Oncology, Berko et al identified the spectrum and clinical significance of clonal and subclonal pathogenic alterations in high-risk neuroblastoma. Study Details The study involved use of a focused high-risk neuroblastoma ...
Researchers have uncovered several biomarkers that may predict how patients with metastatic castration-resistant prostate cancer will respond to the novel combination of ipatasertib and abiraterone, according to a recent study published by Bono et al in European Urology. Background Prostate cancer...
In a study reported in the Journal of Clinical Oncology, Matteo Lambertini, MD, and colleagues identified clinical characteristics of breast cancer in young women carrying germline pathogenic variants in BRCA1 vs BRCA2 and examined the effect of prediagnostic BRCA testing on outcomes. Study...
An innovative combination of treatment strategies involving myeloid cell leukemia (MCL)-1 inhibitors and a kinase inhibitor targeting the SRC oncogene could be effective at triggering cell death in acute myeloid leukemia (AML) cells, according to a recent study published by Hu et al in Signal...
Germline or somatic mutations in the BRCA1 gene might not be key to the initiation of prostate cancer, as previously thought, suggests the first study of its kind, published in BMJ Oncology. If confirmed in further studies, the findings suggest that it may be time to reassess current treatment...
Offering genetic testing to patients with multiple myeloma may help physicians to determine which patients have the most aggressive types of the disease and how to target their malignancy more effectively, according to a recent study published by Kaiser et al in the Journal of Clinical Oncology....
Researchers have found that inhibiting the S6K2 gene could be an effective strategy for managing treatment-resistant melanoma, according to a recent study published by Lipchick et al in Science Translational Medicine. Background Cases of melanoma—the deadliest type of skin cancer—are currently...
Researchers may have uncovered a novel strategy to help predict how well patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC) will respond to new therapies, according to a recent study published by Kato et al in Clinical Cancer Research. Study Methods and Results Researchers developed ...
Researchers have uncovered new heredity genes that may contribute to an increased risk of developing high-grade serous ovarian cancer, according to a recent study published by Subramanian et al in npj Genomic Medicine. Background High-grade serous ovarian cancer is one of the most prevalent and...
The U.S. Food and Drug Administration (FDA) has provided a safety announcement to increase awareness of recent updates to the product labeling of capecitabine and fluorouracil related to the risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency. Background Fluoropyrimidines are a...
First-line treatment with the targeted therapies encorafenib and cetuximab plus a modified leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) chemotherapy regimen may be effective in patients with BRAF V600E–mutated metastatic colorectal cancer, according to recent findings presented by Kopetz et ...
In a study reported in JAMA Network Open, Norton et al found that KRAS G12D and G12V mutations were associated with worse outcomes compared with KRAS wild-type in patients with metastatic pancreatic adenocarcinoma. Study Details The retrospective cohort study used data from a nationwide U.S.-based ...
Although genomic classifier tests may influence risk classifications or treatment decisions in patients with localized prostate cancer, there is a need for more data to better understand cost effectiveness, clinical utility, and their impact on racial and ethnic groups—particularly Black men,...
Researchers may have advanced the understanding of genetic alterations in the BRCA2 gene, according to a recent study published by Huang et al in Nature. The findings could improve the accuracy of genetic testing and allow health-care professionals to offer more precise risk assessments and...
Researchers have discovered of a new type of stem cell in the brain that could lead to the development of more effective treatments in adult patients with glioblastoma, according to a recent study published by Wang et al in Nature. The finding could help explain how adult brain cells take advantage ...
A genetic mutation long believed to drive the development of esophageal cancer may play a protective role early in the disease, according to a recent study published by Ganguli et al in Nature Cancer. The findings could help physicians identify which patients are at greater risk of developing...
First responders who worked at Ground Zero in the aftermath of the 2001 attacks on the World Trade Center in New York City were three times more likely to have genetic changes associated with an increased risk of leukemia compared with other first responders or members of the public who were not...
In the IDENTIFY study, reported in The New England Journal of Medicine, Turriff et al found a high incidence of maternal occult cancer associated with unusual or nonreportable prenatal cell-free DNA (cfDNA) findings in fetal aneuploidy screening. Study Details In the ongoing study, performed at the ...
A novel cell-based immunotherapy may enhance treatment responses and reduce the need for conventional chemotherapy and its associated toxicities in patients with breast cancer, according to a recent study published by Han et al in JAMA Oncology. Study Methods and Results In the phase I clinical...
Functional precision medicine—in which information is obtained from direct perturbations of tumor-derived living cells that enable immediate translatable, personalized data to guide patient therapy—has its roots dating back more than 50 years.1 However, advances in two- and three-dimensional...
Researchers have found that in healthy women, some breast cells that otherwise appear normal may contain chromosome abnormalities typically associated with invasive breast cancer, according to a recent study published by Lin et al in Nature. The findings challenged conventional thinking on the...
The University of Cincinnati Cancer Center announced the launch of a new study funded by a $2.3 million National Cancer Institute (NCI) grant to develop a novel technique to visualize where genetically modified immune cells go after being administered in patients with cancer. Background During...
Researchers have developed an artificial intelligence (AI)-powered computational program that may be capable of predicting the activity of thousands of genes within tumor cells based on standard microscopy images of a biopsy, according to a recent study published by Pizurica et al in Nature...